Core Insights - Femasys Inc. has received approval from the American Medical Association (AMA) for a new Category III CPT code for its FemaSeed intratubal insemination (ITI) procedure, which is set to take effect on January 1, 2027, enhancing reimbursement strategies and patient access to this infertility treatment [1][2] Company Overview - Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally, with a patent-protected portfolio of therapeutic and diagnostic products [3] - The company's fertility portfolio includes FemaSeed ITI, FemSperm, and FemVue, with FemaSeed demonstrating more than double the pregnancy rates of traditional intrauterine insemination (IUI) in clinical trials [3] Product Details - FemaSeed is designed to improve fertilization by delivering sperm directly to the fallopian tube, offering a less invasive and more cost-effective alternative to traditional IUI and in vitro fertilization (IVF) [2] - FemBloc, another product, is the first non-surgical, in-office alternative to surgical sterilization, receiving regulatory approval in Europe, the UK, and New Zealand in 2025 [4] Market Strategy - The approval of the CPT code is expected to support broader clinical adoption and provider utilization of FemaSeed, aiming to reach over 10 million women in the U.S. affected by infertility [2] - Femasys plans to expand its provider footprint and accelerate adoption through the rollout of FemaSeed and the availability of its FemSperm product line [2]

Core Insights - Femasys Inc. has announced a significant initial order valued at approximately $500,000 for the commercial launch of FemBloc in France and the Benelux region, marking continued expansion in key European markets [1][2] - FemBloc is a non-surgical permanent contraceptive solution that addresses a significant unmet need in women's reproductive health, utilizing a patented delivery system to occlude fallopian tubes without the risks associated with surgical procedures [2][4] Company Overview - Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally, with a broad patent-protected portfolio of products [3] - The company is actively commercializing its lead product innovations in the U.S. and key international markets, including FemSeed and FemVue, which have shown high effectiveness and patient satisfaction [3] Product Details - FemBloc is the first and only non-surgical, in-office alternative to surgical sterilization, receiving full regulatory approval in Europe, the UK, and New Zealand in 2025 [4] - The product is designed to be cost-effective, convenient, and significantly safer than traditional surgical options, with no anesthesia, incisions, or recovery time required [2][4] Strategic Partnerships - Femasys has partnered with Kebomed, a leading distributor in Europe, to facilitate the introduction of FemBloc in France and the Benelux region, reflecting a strategic approach to market access and women's healthcare advancement [2][6] - Kebomed has a strong presence across Europe and has been focused on women's health, enhancing its portfolio through partnerships with innovators in minimally invasive gynecology [6][7]